AGIOS PHARMACEUTICALS INC Form SC 13G February 10, 2014

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## SCHEDULE 13G

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES

# 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

# PURSUANT TO RULE 13d-2

(Amendment No. )

Agios Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

00847X104

(CUSIP Number)

December 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- " Rule 13d-1(b)
- " Rule 13d-1(c)
- x Rule 13d-1(d)
- \* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Flagship Ventures Fund 2007, L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power

Number of

Shares -0-6. Shared Voting Power

Beneficially

Owned by 3,860,738 Each 7. Sole Dispositive Power

Reporting

Person -0-8. Shared Dispositive Power

With:

3,860,738

3,860,738

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

12.4%

..

12. Type of Reporting Person (See Instructions)

PN

Page 2 of 10 pages

1. Names of Reporting Persons.

Flagship Ventures 2007 General Partner LLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware 5. Sole Voting Power

## Number of

Shares -0-6. Shared Voting Power

Beneficially

Owned by		3,860,738
Each	7.	Sole Dispositive Power

## Reporting

Person -0-8. Shared Dispositive Power

With:

3,860,738

# Edgar Filing: AGIOS PHARMACEUTICALS INC - Form SC 13G

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

12.4%

..

12. Type of Reporting Person (See Instructions)

00

Page 3 of 10 pages

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Noubar B. Afeyan Ph.D.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

United States

5. Sole Voting Power

Number of

Shares -0-6. Shared Voting Power

Beneficially

Owned by 3,860,738 Each 7. Sole Dispositive Power

Reporting

Person -0-8. Shared Dispositive Power

With:

3,860,738

3,860,738

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

12.4%

..

12. Type of Reporting Person (See Instructions)

IN

Page 4 of 10 pages

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Edwin M. Kania, Jr.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) "

(b) x

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

United States

5. Sole Voting Power

Number of

Shares -0-6. Shared Voting Power

Beneficially

Owned by 3,860,738 Each 7. Sole Dispositive Power

Reporting

Person -0-8. Shared Dispositive Power

With:

3,860,738

3,860,738

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)

12.4%

..

12. Type of Reporting Person (See Instructions)

IN

Page 5 of 10 pages

Item 1(a)Name of Issuer:<br/>Agios Pharmaceuticals, Inc.Item 1(b)Address of Issuer s Principal Executive Offices:<br/>38 Sidney St, 2<sup>nd</sup> Floor<br/>Cambridge, Massachusetts 02139 USAItem 2(a)Name of Person Filing:<br/>The reporting persons are:<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Cambridge<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flagship Ventures Fund 2007, L.P. (Flagship Former<br/>Flagship Former<br/>Flag

Flagship Ventures Fund 2007, L.P. (Flagship Fund)
Flagship Ventures 2007 General Partner LLC (Flagship GP)
Noubar B. Afeyan, Ph.D. (Mr. Afeyan)
Edwin M. Kania, Jr. (Mr. Kania)

#### Item 2(b) Address of Principal Business Office or, if None, Residence:

The address of each of the reporting persons is:

c/o Flagship Ventures One Memorial Drive, 7th Floor Cambridge, Massachusetts 02142

### Item 2(c) Citizenship:

Flagship Fund	Delaware limited partnership		
Flagship GP	Delaware limited liability company		
Mr. Afeyan	U.S. citizen		
Mr. Kania	U.S. citizen		

## Item 2(d) Title of Class of Securities:

This Schedule 13G report relates to the Common Stock, par value 0.001 per share (Common Stock), of Agios Pharmaceuticals, Inc.

# Item 2(e) CUSIP Number:

00847X104

## Item 3 Description of Person Filing:

Not applicable.

## Item 4 Ownership:

## (a) Amount Beneficially Owned:

As of December 31, 2013 Flagship Fund was the record holder of 3,860,738 shares of Common Stock (the Shares ).

As the general partner of Flagship Fund, Flagship GP may be deemed to beneficially own the Shares.

Messrs. Afeyan and Kania, as Managers of Flagship GP with shared voting and dispositive power over the Shares, may be deemed to beneficially own the Shares.

Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares except to the extent of its or his pecuniary interest therein.

## (b) <u>Percent of Class:</u>

Flagship Fund	12.4%
Flagship GP	12.4%
Mr. Afeyan	12.4%
Mr. Kania	12.4%

The ownership percentages above are based on an aggregate of 31,171,169 shares of Common Stock outstanding, as reported in the Issuer s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.

## (c) <u>Number of Shares as to which the Person has:</u>

		NUMBER OF SHARES OF COMMON STOCK		
Reporting Person	(i)	(ii)	(iii)	(iv)
Flagship Fund	0	3,860,738	0	3,860,738
Flagship GP	0	3,860,738	0	3,860,738
Mr. Afeyan	0	3,860,738	0	3,860,738
Mr. Kania	0	3,860,738	0	3,860,738

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of

(iv) Shared power to dispose or to direct the disposition of

# Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ".

Item 6 Ownership of More than Five Percent on Behalf of Another Person: Not applicable.

- Item 7
   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

   Not applicable.
- Item 8 Identification and Classification of Members of the Group:

Each of the Reporting Persons expressly disclaims membership in a Group as defined in Rule 13d-1(b)(ii)(K).

- Item 9 Notice of Dissolution of Group: Not applicable.
- Item 10 Certification:

Not applicable.

This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).

Page 8 of 10 pages

## SIGNATURES

After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

DATED: February 10, 2014

## FLAGSHIP VENTURES FUND 2007, L.P.

By: Flagship Ventures 2007 General Partner LLC, its general partner

By: /s/ Noubar B. Afeyan, Ph. D. Name: Noubar B. Afeyan, Ph. D. Title: Manager

# FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

By: /s/ Noubar B. Afeyan, Ph. D. Name: Noubar B. Afeyan, Ph. D. Title: Manager

/s/ Noubar B. Afeyan, Ph. D NOUBAR B. AFEYAN, PH.D.

/s/ Edwin M. Kania, Jr. EDWIN M. KANIA, JR.

Page 9 of 10 pages

## Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Agios Pharmaceuticals, Inc. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

EXECUTED as of this 10th day of February, 2014.

## FLAGSHIP VENTURES FUND 2007, L.P.

By: Flagship Ventures 2007 General Partner LLC, its general partner

By: /s/ Noubar B. Afeyan, Ph. D. Name: Noubar B. Afeyan, Ph. D. Title: Manager

# FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

By: /s/ Noubar B. Afeyan, Ph. D. Name: Noubar B. Afeyan, Ph. D. Title: Manager

/s/ Noubar B. Afeyan, Ph. D NOUBAR B. AFEYAN, PH.D.

/s/ Edwin M. Kania, Jr. EDWIN M. KANIA, JR.

Page 10 of 10 pages

Exhibit I